Ciclosporin A potentiates venetoclax efficacy in FLT3‐ITD AML by targeting the NFATC1–AKT–mTOR–BCL‐2/MCL‐1 signaling axis

Documenti analoghi

• Targeting MCL ‐1 and MAPK overcomes venetoclax resistance in FLT3 ‐ ITD‐ positive AML cells harbouring activating PTPN11 ( SHP ‐2) mutations
  di: Maximilian Fleischmann, et al.
  Pubblicazione: (2026)
• CPX‐351 +/− gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable‐intermediate risk, FLT3‐ITD negative, AML: A pilot study
  di: Chezi Ganzel, et al.
  Pubblicazione: (2024)
• The expression of Galectin‐9 correlates with mTOR and AMPK in murine colony‐forming erythroid progenitors
  di: Tetsuo Tsukamoto
  Pubblicazione: (2024)
• CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma
  di: Emil Arjun Kumar, et al.
  Pubblicazione: (2024)
• Matching‐adjusted indirect comparisons of efficacy and safety for zanubrutinib versus the combination of fixed‐duration venetoclax and ibrutinib in patients with treatment‐naïve chronic lymphocytic leukaemia
  di: Talha Munir, et al.
  Pubblicazione: (2025)